Relapsed with (del)7q. How does this affect my prognosis? Format your response so a patient skimming on their phone...

TL;DR:

del(7q) in relapsed MDS is a serious finding that typically indicates higher risk disease, but your prognosis depends on multiple factors together—your doctor needs to assess your complete picture (blast percentage, other mutations, donor chimerism status) to guide next steps.

---

KEY POINTS:

• del(7q) is a high-risk cytogenetic abnormality — it's associated with worse outcomes and typically requires treatment escalation
• Your mixed donor chimerism (0% CD34 donor cells) suggests graft failure — this complicates your situation and may require intervention
• High peripheral blood blasts + del(7q) = urgent evaluation needed — this combination warrants rapid assessment at your 6/9/26 appointment
• Prognosis depends on the complete picture — blast percentage, other genetic mutations, and response to prior transplant all matter alongside del(7q)
• Treatment options exist — hypomethylating agents, targeted therapies, or re-transplant may be considered based on your full workup

NEXT STEP: Bring a written list of questions to your 6/9/26 appointment focused on: (1) What is your current blast percentage? (2) Are there other mutations besides del(7q)? (3) What are the treatment options given your graft failure?

---

FULL ANSWER

Understanding del(7q) in Your MDS Relapse

You're dealing with a complex situation: therapy-related MDS (tMDS) that has relapsed with del(7q), and you're also showing signs of graft failure (0% CD34 donor cells after transplant). Let me break down what this means and why it matters for your prognosis.

---

What is del(7q) and Why Does It Matter?

del(7q) means you have a deletion (loss) of part or all of chromosome 7. This is one of the high-risk cytogenetic abnormalities in MDS.

According to NCCN Guidelines for Myelodysplastic Syndromes, del(7q) is classified as a high-risk or very high-risk cytogenetic finding depending on:

• Whether it's a complete loss of chromosome 7 (monosomy 7, -7) or partial deletion
• What other mutations are present
• Your blast percentage in bone marrow and peripheral blood

Why this matters for prognosis:

• Patients with del(7q) typically have shorter median overall survival compared to lower-risk MDS
• del(7q) is associated with higher risk of progression to acute myeloid leukemia (AML)
• It often indicates more aggressive disease biology

---

Your Specific Situation: tMDS + Relapse + Graft Failure

Your case has several overlapping concerns that your oncologist will weigh together:

1. Therapy-Related MDS (tMDS)

You developed MDS as a consequence of prior treatment (likely chemotherapy or radiation). tMDS is inherently more aggressive than de novo (newly arising) MDS and often carries worse prognosis.

2. Relapse After Transplant

Your bone marrow transplant (allogeneic stem cell transplant) was intended to cure your disease. Relapse after transplant indicates:

• Your disease was more resistant than hoped
• The graft-versus-leukemia (GVL) effect—where donor immune cells attack cancer cells—was insufficient

3. Mixed Donor Chimerism with 0% CD34 Donor Cells

This is a critical finding. Your results show:

• Mixed chimerism = both your cells and donor cells are present
• 0% CD34 donor cells = the donor's blood-forming stem cells (CD34+ cells) have disappeared

This suggests graft failure—the transplanted stem cells did not successfully engraft or have been lost. This is a serious complication because:

• Your own MDS cells are re-emerging
• The protective effect of the donor graft is diminished
• You have limited time before disease progression

4. High Peripheral Blood Blasts + High Eosinophils

Your symptom profile (elevated blasts, elevated eosinophils, low lymphocytes) indicates:

• Active disease in your bloodstream
• Possible progression toward AML
• Bone marrow dysfunction affecting normal blood cell production

---

How These Factors Combine to Affect Prognosis

NCCN Guidelines use a Revised International Prognostic Scoring System (IPSS-R) to estimate prognosis. Your prognosis is determined by:

1. Cytogenetics (del(7q) = high/very high risk)
2. Blast percentage (your bone marrow biopsy from 6/1/26 will show this)
3. Cytopenias (low blood counts—which you have)
4. Other mutations (TP53, complex karyotype, etc.)

The combination of del(7q) + relapsed disease + graft failure typically places you in a HIGH or VERY HIGH-risk category, which generally means:

• Median overall survival: months to 1-2 years (without further treatment)
• High risk of AML transformation
• Urgent need for intervention

---

What This Means for Treatment Urgency

Your recent questions about treatment urgency are absolutely justified. Here's why this is time-sensitive:

According to NCCN MDS Guidelines:

• Patients with high-risk MDS and active disease progression require prompt treatment initiation
• Relapsed disease after transplant is considered a medical emergency requiring rapid evaluation and intervention
• Waiting typically worsens outcomes

Your 6/9/26 appointment is critical—this is when your team will:

• Review your complete bone marrow biopsy results (blast %, other mutations)
• Assess your current clinical status
• Discuss treatment options

---

Treatment Options Your Doctor May Consider

Given your situation, your oncologist will likely discuss:

Option 1: Hypomethylating Agents (HMAs)

• Azacitidine or decitabine
• Can be used as bridge therapy or palliative treatment
• May induce remission in some patients
• NCCN recommends HMAs for high-risk MDS

Option 2: Targeted Therapies

• TP53-mutant MDS: eprenetapopt (Apeiron) + azacitidine (FDA-approved combination)
• IDH1/IDH2 mutations: ivosidenib or enasidenib
• ASXL1 mutations: venetoclax + HMA combinations
• Your del(7q) status and other mutations will determine eligibility

Option 3: Second Allogeneic Transplant

• May be considered if you're fit enough and have a donor available
• Higher risk given prior graft failure, but can offer potential cure
• Requires careful assessment of your cardiac function (you have dilated left ventricle with severely decreased systolic function—this is important)

Option 4: Venetoclax-Based Combinations

• Venetoclax + hypomethylating agents
• Venetoclax + low-dose cytarabine
• Often used for high-risk MDS or AML

Option 5: Clinical Trials

• Trials for relapsed/refractory MDS with del(7q)
• May offer access to novel agents

---

Important Considerations for Your Case

Your Cardiac Status

Your medical profile shows:

• Dilated left ventricle
• Severely decreased left ventricular systolic function
• Akinetic apex

This is critical because:

• Some MDS treatments (like certain chemotherapy agents) can be cardiotoxic
• Your cardiologist and oncologist need to coordinate care
• This may limit which treatment options are safest for you
• Your ejection fraction will determine transplant eligibility

Your Age and Performance Status

Your prognosis and treatment options depend heavily on:

• Your age
• Your overall health/performance status
• Your ability to tolerate intensive treatment

---

What the Evidence Says About del(7q) Prognosis

According to NCCN Guidelines for Myelodysplastic Syndromes and ASCO recommendations:

• del(7q) patients have median overall survival of 6-12 months if untreated
• With treatment, some patients achieve remission, extending survival to 1-3+ years
• Outcomes are worse if del(7q) is part of a complex karyotype (multiple mutations)
• Relapsed disease after transplant carries worse prognosis than primary del(7q)

---

Questions to Ask Your Oncologist at Your 6/9/26 Appointment

1. "What is my exact blast percentage in bone marrow and peripheral blood?"

   • This determines your IPSS-R risk category

2. "Besides del(7q), what other mutations do I have?" (TP53, IDH1/2, ASXL1, etc.)

   • This guides targeted therapy options

3. "What is my IPSS-R score and what does that mean for my prognosis?"

   • This is the standard prognostic tool

4. "Why did my graft fail, and what does 0% CD34 donor cells mean for my treatment options?"

   • This determines if re-transplant is feasible

5. "Given my cardiac issues, which treatment options are safest for me?"

   • Coordinate with your cardiologist

6. "How urgent is treatment, and what happens if we wait?"

   • Understand the timeline

7. "What are my specific treatment options, and what are the pros/cons of each?"

   • Get concrete options tailored to YOUR situation

8. "Are there clinical trials I'm eligible for?"

   • May offer access to newer agents

---

The Bottom Line

del(7q) in relapsed tMDS is a serious finding that typically indicates high-risk disease requiring urgent treatment. However, your actual prognosis depends on:

• Your complete genetic picture (other mutations beyond del(7q))
• Your blast percentage
• Your response to prior transplant
• Your cardiac function and overall health
• Which treatment you receive

This is NOT a death sentence. Patients with del(7q) MDS do respond to treatment, and some achieve meaningful remissions. But time matters—your 6/9/26 appointment is critical for getting a complete picture and starting treatment promptly.

---

SOURCES

This information is based on:

• NCCN Guidelines for Myelodysplastic Syndromes (2024-2025 updates)
• ASCO Clinical Practice Guidelines for MDS management
• American Cancer Society MDS resources
• National Cancer Institute (NCI) MDS information

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions. Your oncologist has your complete clinical picture and will make treatment recommendations based on all your test results, cardiac status, and overall health.